Liver Disease Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2032

Liver Disease Therapeutics Market by Product (Antiviral Drugs, Corticosteroids, Immunosuppressants, Chemotherapy Drugs, Immunoglobulins, and Others), Disease (Hepatitis, Autoimmune Disorders, Cancer, Non-alcoholic Fatty Liver Disease, and Others), End-Users (Hospital Pharmacy, Retail Drug Stores, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of liver disease and increasing consumption of alcohol and improper diet.

The liver disease therapeutics market was valued at USD 20,020.75 million in 2024, growing at a CAGR of 5.32% during the forecast period from 2025 to 2032 to reach USD 30,113.63 million by 2032. The global demand for liver disease therapeutics is being driven primarily by the rising prevalence of liver-related conditions. Key contributing factors include increasing alcohol consumption, unhealthy dietary habits, and heightened awareness of liver diseases and their management. Growing efforts in early diagnosis, improved access to healthcare, and public health initiatives aimed at liver disease prevention are further supporting market expansion. Additionally, advancements in therapeutic options and increased investments in research and development are expected to propel the growth of the liver disease therapeutics market during the forecast period from 2025 to 2032.

Liver Disease Therapeutics Market Dynamics:

According to the World Health Organization (WHO) 2024, approximately 254 million people were living with chronic hepatitis B infection in 2022, with around 1.2 million new infections each year. Additionally, a recent study published in PubMed Central titled “Global incidence and prevalence of nonalcoholic fatty liver disease” estimated the global incidence of nonalcoholic fatty liver disease (NAFLD) at 47 cases per 1,000 population. The same study stated that the prevalence of NAFLD among adults is 32%, with a higher rate in males (40%) compared to females (26%). The growing number of patients with liver diseases directly translates to a higher demand for treatments, especially since many liver conditions, including hepatitis B and C, fatty liver disease, and cirrhosis, require long-term management.

Another factor contributing to the growth of the liver disease therapeutics market is the increasing consumption of alcohol and improper diet. According to the WHO 2024 data, approximately 400 million people (7% of the global population aged 15 years and older) live with alcohol use disorders, of which 209 million people (3.7% of the adult population) suffer from alcohol dependence. Excessive alcohol intake can lead to fat accumulation in liver cells, a condition known as fatty liver disease, which is the earliest stage of alcohol-related liver disease. Consequently, the rising prevalence of alcohol consumption and poor dietary habits is expected to further boost the demand for liver disease therapeutics in the coming years.

Despite these growth drivers, the liver disease therapeutics market faces challenges such as stringent regulatory approval processes and the potential side effects associated with liver disease therapies, which may hinder market expansion.

Liver Disease Therapeutics Market Segment Analysis:

Liver Disease Therapeutics Market by Product (Antiviral Drugs, Corticosteroids, Immunosuppressants, Chemotherapy Drugs, Immunoglobulins, and Others), Disease (Hepatitis, Autoimmune Disorders, Cancer, Non-alcoholic Fatty Liver Disease, and Others), End-Users (Hospital Pharmacy, Retail Drug Stores, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the liver disease therapeutics market, the chemotherapy drugs segment is projected to capture a substantial revenue share in 2024. According to Globocan 2022 data, approximately 866,136 individuals were diagnosed with liver cancer globally in 2022. This rising prevalence is a key factor driving the demand for chemotherapy drugs.

Chemotherapy remains a standard treatment option for liver cancer, particularly in advanced stages or when surgery is not feasible. Its effectiveness in shrinking tumors, slowing disease progression, and improving survival rates has made it a preferred therapeutic approach for various liver conditions.

Furthermore, ongoing investments in research and development have led to the introduction of more effective chemotherapy agents. Continuous innovation ensures that chemotherapy remains at the forefront of liver disease treatment. For example, in March 2023, Auransa Inc. partnered with the University of Southern California (USC) to initiate a Phase I clinical trial evaluating AU409, a novel therapy for liver cancers and solid tumors with liver-dominant disease.

Given these factors the increasing incidence of liver cancer, proven therapeutic efficacy, and advancements in drug development the chemotherapy drugs segment is expected to experience significant growth, thereby propelling the overall liver disease therapeutics market during the forecast period.

North America is expected to dominate the overall liver disease therapeutics market:

North America is projected to hold the largest share of the liver disease therapeutics market in 2024. This dominance is primarily driven by the rising prevalence of liver disorders in the region, increasing patient awareness of early diagnosis and disease management, robust research and development (R&D) initiatives, high alcohol consumption rates, and an aging population.

According to the Centers for Disease Control and Prevention (CDC) 2023 data, approximately 880,000 people in the United States live with chronic hepatitis B. The growing burden of liver diseases such as hepatitis is fueling demand for effective treatment and management solutions, thereby driving market growth.

Furthermore, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) 2024 reported that 221.3 million individuals aged 12 and older in the U.S. (78.5% of this age group) have consumed alcohol at some point in their lives. Excessive alcohol consumption is a major risk factor for various liver conditions, increasing the need for liver disease therapeutics.

Strategic collaborations among key market players in North America are further accelerating the development of innovative treatments. For instance, in February 2024, Gilead Sciences, Inc. entered into a definitive agreement to acquire CymaBay Therapeutics, Inc. for USD 32.50 per share in cash, expanding Gilead’s portfolio of liver disease therapeutics.

Collectively, the high prevalence of liver diseases, growing patient awareness, increasing alcohol consumption, significant R&D investments, and strategic industry collaborations are key factors propelling the growth of the liver disease therapeutics market in North America during the forecast period.

Liver Disease Therapeutics Market Key Players:

Some of the key market players operating in the liver disease therapeutics market include Abbott, Gilead Sciences, GSK plc., F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., Novartis AG, Madrigal Pharmaceuticals, Sanofi, Takeda Pharmaceuticals, Amneal Pharmaceuticals, Inc., AbbVie Inc., Alnylam Pharmaceuticals Inc., Merck & Co., Inc., Eli Lilly and Company, Exelixis, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Bayer AG, and Viatris Inc.

Recent Developmental Activities in the Liver Disease Therapeutics Market:

In June 2024, Ipsen’s Iqirvo® received the U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis.

In March 2024, Madrigal Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

Key Takeaways From The Liver Disease Therapeutics Market Report Study

Market size analysis for current liver disease therapeutics market size (2024), and market forecast for 8 years (2025 to 2032)

Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.

Key companies dominating the liver disease therapeutics market.

Various opportunities available for the other competitors in the liver disease therapeutics market space.

What are the top-performing segments in 2024? How these segments will perform in 2032?

Which are the top-performing regions and countries in the current liver disease therapeutics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for liver disease therapeutics market growth in the coming future?

Target Audience Who Can Be Benefited From This Liver Disease Therapeutics Market Report Study

Liver disease therapeutics product providers

Research organizations and consulting companies

Liver disease therapeutics related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and traders dealing in liver disease therapeutics

Various end-users who want to know more about the liver disease therapeutics market and the latest technological developments in the liver disease therapeutics market.

Frequently Asked Questions For The Liver Disease Therapeutics Market:

1. What is meant by liver disease therapeutics?

Liver disease therapeutics refer to the various treatments and interventions used to manage, treat, and potentially cure diseases and conditions affecting the liver. These therapeutics can include a wide range of approaches depending on the specific liver condition being addressed.

2. What is the market for liver disease therapeutics?

The liver disease therapeutics market was valued at USD 20,020.75 million in 2024, growing at a CAGR of 5.32% during the forecast period from 2025 to 2032 to reach USD 30,113.63 million by 2032.

3. What are the drivers for the global liver disease therapeutics market?

The liver disease therapeutics market is primarily being boosted by the increasing prevalence of liver diseases around the globe. Additionally, increasing consumption of alcohol and improper diet, and growing awareness regarding liver diseases are some of the key factors, which are contributing to the growth of the liver disease therapeutics market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global liver disease therapeutics market?

Some of the key market players operating in the liver disease therapeutics market include Abbott, Gilead Sciences, GSK plc., F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., Novartis AG, Madrigal Pharmaceuticals, Sanofi, Takeda Pharmaceuticals, Amneal Pharmaceuticals, Inc., AbbVie Inc., Alnylam Pharmaceuticals Inc., Merck & Co., Inc., Eli Lilly and Company, Exelixis, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Bayer AG, and Viatris Inc.

5. Which region has the highest share in the global liver disease therapeutics market?

North America is expected to dominate the overall liver disease therapeutics market during the forecast period, 2025 to 2032. This is due to the growing prevalence of liver disorders in the region. Additionally, growing awareness among patients regarding the importance of early and accurate diagnosis and disease management of liver disorders, the presence of robust research and development initiatives, increasing prevalence of alcohol consumption, and the presence of an aging population are some of the key factors driving the growth of the liver disease therapeutics market in North America.